Company Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome.
In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers.
It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Peter Altman |
Contact Details
Address: 320 Soquel Way Sunnyvale, California 94085 United States | |
| Phone | 650 226 0120 |
| Website | biocardia.com |
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U507 |
| ISIN Number | US09060U6064 |
| Employer ID | 23-2753988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter A. Altman Ph.D. | Chief Executive Officer, President and Director |
| David McClung | Chief Financial Officer |
| Edward M. Gillis | Senior Vice President of Devices |
| Miranda Peto Benvenuti | Investor Relations Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 8-K | Current Report |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 8-K | Current Report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 10, 2026 | 8-K | Current Report |